GET DAILY SIGNALSPliant Therapeutics (PLRX) Declines -20.6% Over 30 Days as Focus Shifts to 2027 Readouts
Key Takeaways
- PLRX shares fell roughly 20.6% over the last 30 days, moving from about $1.08 down to approximately $0.86.
- The decline continues a longer trend that has the stock trading below the $1.00 per-share level.
- Attention centers on PLN-101095, the lead oncology candidate in the FORTIFY Phase 1b trial, where interim efficacy data is not expected until 2027.
- Recent updates, including a new chief medical officer, a research executive hire, and an ESMO poster, provided no new clinical efficacy information.
- Weiss Ratings maintained a "Sell" rating on the stock in mid-October.
- With around $172 million in cash and a market capitalization near $56 million, the valuation highlights significant single-asset execution risk.
- Additional context on valuation and estimates is available on Pliant’s Price Targets, Earnings, and Forecast pages.
A Closer Look at Pliant Therapeutics and Its Current Position
Pliant Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco focused on integrin-based therapeutics. Its lead program, PLN-101095, is a small-molecule dual-selective inhibitor of the αvβ8 and αvβ1 integrins being studied in combination with pembrolizumab for patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The candidate is in the FORTIFY Phase 1b indication-expansion trial covering non-small cell lung cancer, high tumor mutational burden tumors, and clear cell renal cell carcinoma cohorts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Preclinical work centers on tissue-specific delivery of therapeutic payloads such as siRNA using integrin receptor-binding molecules. The company had been known for bexotegrast in idiopathic pulmonary fibrosis and primary sclerosing cholangitis, but discontinued the BEACON-IPF program in 2025 after a safety review and cut its workforce by roughly 45%. Investors now track the stock mainly for oncology data and the emerging RNAi-delivery platform.
PLRX Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, PLRX moved from approximately $1.08 to about $0.86, a decline of roughly 20.6%. The drop included a sharp session on October 14 when the stock fell more than 8% on higher volume, followed by continued pressure through the rest of the month.
The three-month picture shows a similar pattern. Shares started near $1.08 in late July, rose briefly toward $1.19 in mid-August, then gave back those gains. By late October the stock was again near $0.86, leaving it down approximately 20% for the quarter and trading firmly below $1.00.
What Influenced the Recent Price Action
The pullback occurred against a backdrop of limited near-term catalysts rather than any single negative data release. In mid-October the company announced a poster at the European Society for Medical Oncology Congress 2026. The abstract was labeled a “trial in progress,” describing study design and enrollment without efficacy results. For investors waiting on clinical data, the lack of new readouts reduced enthusiasm.
Other updates reinforced that meaningful news remains months away. A new chief medical officer was appointed in early October and a senior vice president of research later in the month. Weiss Ratings reiterated a “Sell” rating on October 15. With no efficacy data due until 2027 and the stock below $1.00, sentiment stayed cautious given the single-asset profile.
The Broader Quarterly Trend and Company Transition
The multi-month move reflects Pliant’s shift from a fibrosis-focused company to a single-asset oncology story. After discontinuing bexotegrast and completing the restructuring, value is now tied almost entirely to PLN-101095 and its potential in checkpoint-refractory cancers. Early signals from December 2025, including four responses among ten heavily pretreated patients, supported the rationale, though the sample was small and the definitive readout is still years away.
During the quarter, short rallies were met with selling as investors considered the long wait for data, ongoing cash burn, and possible dilution. The mid-August move toward $1.19 did not hold, and the stock resumed its decline as the catalyst calendar thinned.
What to Watch Next for PLRX
The main upcoming driver remains the FORTIFY Phase 1b trial of PLN-101095. Enrollment updates, any additional combination or dose-expansion data, and the timing of the interim efficacy readout expected in 2027 will likely influence sentiment. Cash runway and potential financing activity also warrant attention given the development stage and sub-$1 share price.
Operational items include integration of the new chief medical officer and research leadership, progress on the preclinical siRNA-delivery platform, and any regulatory or partnership news. Broader biotech sector conditions and interest-rate trends may affect risk appetite for early-stage companies as well.
Reviewing AI Trading Strategies in Practice
In my research process, I often review Tickeron’s Trending AI Robots page to see how top-performing automated systems are positioned across the market. The page curates a focused selection of the highest-performing bots from a platform running hundreds of strategies on thousands of tickers, highlighting those most relevant to current conditions. These systems range from short-term technical models to longer-horizon approaches, with performance tracked continuously so the list reflects prevailing market dynamics. This helps provide additional context when evaluating names like PLRX.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PLRX's RSI Indicator descending into oversold zone
The RSI Indicator for PLRX moved into overbought territory on October 26, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in 197 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
PLRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PLRX as a result. In 67 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
PLRX moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PLRX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PLRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. PLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.361) is normal, around the industry mean (3.037). P/E Ratio (-0.571) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. PLRX's P/S Ratio (3333.333) is slightly higher than the industry average of (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases
Industry Biotechnology
Advertisement